# Luma Group

Luma Group is a Private Equity based in New York, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2002
- **Assets under management:** Undisclosed
- **Website:** lumagroup.com
- **LinkedIn:** https://www.linkedin.com/company/luma-lighting-group

## Regulatory record

- **CRD number:** 328200
- **SEC file number:** 802-128958
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/328200

## About

Luma Group is a multistage investment firm focused on biotechnology. It brings together scientific insight and computation to shape both its investment strategy and the companies it backs. The firm partners with teams translating breakthrough science into therapies, diagnostics, and medical devices, providing support beyond financial capital.

## Sectors

- Biotechnology
- AI/ML
- Digital Health

## People

- Josh Fink — Founder & Managing Member
- Themasap Khan — PhD, Co-Founder & Partner
- Jamie Kasuboski — PhD, Partner & Head of Research
- Bill Ryan — Chief Financial Officer
- John Gomez — Senior Associate
- Miguel "Miggy" Chuapoco — PhD, Associate
- Richie Santry — Chief of Staff
- Tamara Young — Executive Assistant
- James "JJ" Stankowicz — PhD, Head of AI & Engineering
- Negin Mokhtari — PhD, Venture Partner & Chief Strategy Officer of LABI
- Nora McCarthy — Administrative Assistant
- Richard Ebright — MD, PhD, Science Fellow
- Rishabh Mishra — MD, Clinical Advisor

## Questions

### How does Luma Group source its investments?

Luma sources opportunities through a combination of deep biological conviction and computational analysis. The firm built LABI, a proprietary AI system, to accelerate data analysis, validate scientific breakthroughs, and identify undervalued potential in early to clinical-stage biotechnology companies. This dual scientific-computational approach informs both the investment strategy and the selection of portfolio companies.

### Does Luma Group make fund commitments, or does it invest directly?

Luma Group's disclosures indicate a direct investment model. The firm describes its role as a hands-on partner that provides strategic, operational, and scientific support beyond financial capital to portfolio companies. There is no public evidence of a fund-of-funds strategy or traditional LP relationships with external GPs.

### What stages of biotechnology does Luma Group target?

Luma describes itself as a multi-stage investment firm focused on biotechnology, without limiting itself to early-stage venture or late-stage growth. Its portfolio spans companies developing platforms, like Curve Biosciences' chronic disease detection technology, as well as those advancing novel therapies, such as Coultreon Bio's multi-pathway immunological candidates. The firm evaluates both preclinical and clinical-stage opportunities.

### Which sectors outside of biotechnology does Luma Group consider?

Luma Group's public materials, including its website and published research, are restricted entirely to biotechnology and adjacent computational biology. The firm states an explicit focus on therapies, diagnostics, and medical devices. There is no indication of activity in sectors such as software, financial services, consumer goods, or energy.

## Related profiles

- [Lowe Wealth Advisors](https://altss.com/profile/lowe-wealth-advisors)
- [Luna Capital](https://altss.com/profile/luna-capital)

---

Last updated: 2026-08-11T15:07:19.634Z

Canonical page: https://altss.com/profile/luma-group

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology